Patent: 8,853,412
✉ Email this page to a colleague
Summary for Patent: 8,853,412
Title: | Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
Abstract: | The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them. |
Inventor(s): | Schwink; Lothar (Frankfurt am Main, DE), Bossart; Martin (Frankfurt am Main, DE), Glombik; Heiner (Frankfurt am Main, DE), Gossel; Matthias (Frankfurt am Main, DE), Kadereit; Dieter (Frankfurt am Main, DE), Klabunde; Thomas (Frankfurt am Main, DE), Maier; Thomas (Frankfurt am Main, DE), Stengelin; Siegfried (Frankfurt am Main, DE) |
Assignee: | Sanofi (Paris, FR) |
Application Number: | 14/048,425 |
Patent Claims: | see list of patent claims |
Details for Patent 8,853,412
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amryt Pharmaceuticals Dac | MYALEPT | metreleptin | For Injection | 125390 | 02/24/2014 | ⤷ Try a Trial | 2032-10-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |